Chronic Hepatitis C

REFERENCES

• 1 Alter M, Kruszon-Moran D, Nainan O et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med. 1999;  341 556-562
• 2 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384.  Gastroenterology. 1997;  112 463-472
• 3 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.  Lancet. 1997;  349 825-832
• 4 Sherman K E, Rouster S D, Chung R T, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.  Clin Infect Dis. 2002;  34 831-837
• 5 Lombardi M, Cerrai T, Geatti S et al.. Results of a national epidemiological investigation on HCV infection among dialysis patients.  J Nephrol. 1999;  12 322-327
• 6 McHutchinson J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.  N Engl J Med. 1998;  339 1485-1492
• 7 Fried M W, Shiffman M L, Reddy K R et al.. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 8 Saldanha J, Lelie N, Heath A et al.. Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA.  Vox Sang. 1999;  76 149-158
• 9 Davis G L, Balart L A, Schiff E R et al.. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial.  N Engl J Med. 1989;  321 1501-1506
• 10 Shiffman M L. PEGylated interferons: what role will they play in the treatment of chronic hepatitis C?.  Curr Gastroenterol Rep. 2001;  3 30-37
• 11 Manns M P, McHutchinson J G, Gordon S C et al.. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.  Lancet. 2001;  358 958-965
• 12 Shiffman M L, Hofmann C M, Thompson E B et al.. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C.  Hepatology. 1997;  26 780-785
• 13 Charlton M. Natural history of hepatitis C and outcomes following liver transplantation.  Clin Liver Dis. 2003;  7 585-602